AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10520780 — intervention group
Group type: COMPARATOR
Intervention: Low-dose dobutamine echocardiography (LDDE)
Number of subjects: 52
Study 10520780 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up echocardiography
Number of subjects: 52
Study 8866632 — intervention group
Group type: COMPARATOR
Intervention: 400 mg PROP
Number of subjects: 20
Study 8866632 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg PROP
Number of subjects: 20
Study 8866632 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg PROP + 100 mg CAFF
Number of subjects: 20
Study 8866632 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg PROP + 150 mg CAFF
Number of subjects: 20
Study 8866632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1727457 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive videodisc preparation
Number of subjects: 35
Study 1727457 — intervention group
Group type: COMPARATOR
Intervention: Noninteractive videotape preparation
Number of subjects: 35
Study 1727457 — intervention group
Group type: COMPARATOR
Intervention: Surgeon-only consultation
Number of subjects: 35
Study 6369216 — intervention group
Group type: EXPERIMENTAL
Intervention: BSS Plus with glucose = 400 mg/dl
Number of subjects: 20
Study 6369216 — intervention group
Group type: COMPARATOR
Intervention: BSS Plus with glucose = 100 mg/dl
Number of subjects: 20
Study 31475320 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate laparoscopic cholecystectomy (LC)
Number of subjects: 64
Study 31475320 — intervention group
Group type: COMPARATOR
Intervention: Same admission delayed laparoscopic cholecystectomy (LC)
Number of subjects: 64
Study 28647788 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg IV-dexamethasone (group dexa)
Number of subjects: 110
Study 28647788 — intervention group
Group type: COMPARATOR
Intervention: IV-isotonic saline (group placebo)
Number of subjects: 110
Study 27149585 — intervention group
Group type: EXPERIMENTAL
Intervention: WSEB exercises (3 times per week, 40 minutes per session for 6 months)
Number of subjects: 138
Study 27149585 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 138
Study 25471761 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised pelvic floor muscle training
Number of subjects: 0
Study 25471761 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22622275 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 20
Study 22622275 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 20
Study 20514986 — intervention group
Group type: EXPERIMENTAL
Intervention: MCPs-treated diabetics
Number of subjects: 200
Study 20514986 — intervention group
Group type: EXPERIMENTAL
Intervention: MCPs-treated diabetics with hypertension
Number of subjects: 200
Study 20514986 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated diabetics
Number of subjects: 200
Study 20514986 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated diabetics with hypertension
Number of subjects: 200
Study 17506593 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg/day
Number of subjects: 38
Study 17506593 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/day
Number of subjects: 38
Study 17506593 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 38
Study 16242593 — intervention group
Group type: EXPERIMENTAL
Intervention: Water gargling
Number of subjects: 387
Study 16242593 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine gargling
Number of subjects: 387
Study 16242593 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 387
Study 12072903 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG Fresenius
Number of subjects: 50
Study 12072903 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin Mérieux
Number of subjects: 50
Study 10086537 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic calcitonin (40 Medical Research Council Standard Units subcutaneously per day in 14-day cycles)
Number of subjects: 61
Study 10086537 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 61
Study 7672156 — intervention group
Group type: EXPERIMENTAL
Intervention: T undecanoate (40 mg three times per day)
Number of subjects: 48
Study 7672156 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM (10 mg two times per day)
Number of subjects: 48
Study 7672156 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG (75 IU/d)
Number of subjects: 48
Study 7672156 — intervention group
Group type: EXPERIMENTAL
Intervention: T undecanoate and TAM
Number of subjects: 48
Study 7672156 — intervention group
Group type: EXPERIMENTAL
Intervention: T undecanoate and hMG
Number of subjects: 48
Study 7672156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 1796127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependence Index (DI) measured at 48 hours, 4 weeks, and 8 weeks post-cessation
Number of subjects: 0
Study 1796127 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving measure obtained 48 hours after smoking cessation
Number of subjects: 0
Study 1796127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependence Index (DI)
Number of subjects: 0
Study 6347779 — intervention group
Group type: EXPERIMENTAL
Intervention: Interruption of continuous subcutaneous insulin infusion
Number of subjects: 8
Study 6347779 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin supplements administered via the pump after resetting at basal rate
Number of subjects: 8
Study 6347779 — intervention group
Group type: COMPARATOR
Intervention: Control test with the pump functioning normally
Number of subjects: 8
Study 30382712 — intervention group
Group type: EXPERIMENTAL
Intervention: BRIGHTEN Heart team intervention plus membership in Generations
Number of subjects: 250
Study 30382712 — intervention group
Group type: COMPARATOR
Intervention: Generations only (comparison group)
Number of subjects: 250
Study 28895568 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (TCT) for 40 hours
Number of subjects: 44
Study 28895568 — intervention group
Group type: COMPARATOR
Intervention: Computer games control (CG)
Number of subjects: 44
Study 26648386 — intervention group
Group type: COMPARATOR
Intervention: Panoramic imaging (non-scan group)
Number of subjects: 230
Study 26648386 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone Beam CT (CBCT) (scan group)
Number of subjects: 230
Study 24809408 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine (GL) supplementation for 7 days
Number of subjects: 80
Study 24809408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 22382187 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-daily biphasic human insulin (30/70, BHI)
Number of subjects: 50
Study 22382187 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal detemir and bolus aspart (BB)
Number of subjects: 50
Study 20003492 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-curricular physical activity intervention (2 hours a week for 18 weeks, brisk walking 3200 m twice weekly during curriculum lessons)
Number of subjects: 0
Study 20003492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 17143004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive flexibility
Number of subjects: 63
Study 17143004 — intervention group
Group type: COMPARATOR
Intervention: Age, quadriceps strength of the paretic side, current physical activity level
Number of subjects: 63
Study 15886447 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularity Index 1 (RI1) in back pain patients
Number of subjects: 21
Study 15886447 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularity Index 2 (RI2) in back pain patients
Number of subjects: 21
Study 15886447 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait information flow characteristics in back pain patients
Number of subjects: 21
Study 15886447 — intervention group
Group type: COMPARATOR
Intervention: Regularity Indices (RI1 and RI2)
Number of subjects: 21
Study 12032542 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-day nap between the second and third sessions
Number of subjects: 0
Study 12032542 — intervention group
Group type: EXPERIMENTAL
Intervention: Shifting target stimuli to an untrained region of visual space
Number of subjects: 0
Study 12032542 — intervention group
Group type: COMPARATOR
Intervention: Repeated within-day testing without intervention
Number of subjects: 0
Study 10623052 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced access to primary care
Number of subjects: 443
Study 10623052 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 443
Study 7875757 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 26
Study 7875757 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 26
Study 2193979 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine (half dose)
Number of subjects: 139
Study 2193979 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine (full dose)
Number of subjects: 139
Study 7471920 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART program
Number of subjects: 56
Study 7471920 — intervention group
Group type: EXPERIMENTAL
Intervention: PUSH program
Number of subjects: 56
Study 7471920 — intervention group
Group type: COMPARATOR
Intervention: Standard Reading group
Number of subjects: 56
Study 7471920 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 56
Study 30834817 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive decision tool intervention for FTASD treatment
Number of subjects: 200
Study 30834817 — intervention group
Group type: COMPARATOR
Intervention: Text-based control on shoulder dislocations and treatments
Number of subjects: 200
Study 27921445 — intervention group
Group type: EXPERIMENTAL
Intervention: MJ-exposed infants
Number of subjects: 1867
Study 27921445 — intervention group
Group type: COMPARATOR
Intervention: MJ-unexposed infants
Number of subjects: 1867
Study 25833773 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (20 g/d)
Number of subjects: 27
Study 25833773 — intervention group
Group type: COMPARATOR
Intervention: Gelatin protein supplementation
Number of subjects: 27
Study 25833773 — intervention group
Group type: EXPERIMENTAL
Intervention: Both whey and gelatin groups
Number of subjects: 27
Study 25833773 — intervention group
Group type: COMPARATOR
Intervention: Whey protein vs. Gelatin protein
Number of subjects: 27
Study 23890573 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-antiplatelet therapy (TAT; aspirin, clopidogrel, and cilostazol)
Number of subjects: 1399
Study 23890573 — intervention group
Group type: COMPARATOR
Intervention: Dual-antiplatelet therapy (aspirin and clopidogrel)
Number of subjects: 1399
Study 22174434 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 0
Study 22174434 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study 19619377 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-based, nurse-led educational, care coordination palliative care intervention model, provided weekly for the first month and then monthly until death, including bereavement follow-up call to the caregiver.
Number of subjects: 279
Study 19619377 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 279
Study 17502727 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral drug resistance
Number of subjects: 195
Study 17502727 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-class resistance
Number of subjects: 195
Study 17502727 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCR4-using HIV-1 strains
Number of subjects: 195
Study 15478000 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg daily)
Number of subjects: 48
Study 15478000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11125189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavitated lesions
Number of subjects: 54
Study 11125189 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesions >0.5 mm from the enamel‐dentine junction
Number of subjects: 54
Study 11125189 — intervention group
Group type: COMPARATOR
Intervention: Non-cavitated lesions
Number of subjects: 54
Study 9676346 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg sustained release theophylline (Bronchoretard) administered in a fasting state
Number of subjects: 18
Study 9676346 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg sustained release theophylline (Bronchoretard) administered after a standard meal
Number of subjects: 18
Study 9676346 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg sustained release theophylline (Bronchoretard) administered after a high-caloric fat evening meal
Number of subjects: 18
Study 9676346 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of food with theophylline
Number of subjects: 18
Study 7734463 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced clinical services (more frequent and intensive group therapy, or adding individual treatment services)
Number of subjects: 303
Study 7734463 — intervention group
Group type: COMPARATOR
Intervention: Standard group therapy treatment program
Number of subjects: 303
Study 3057924 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine as an adjunct to fluphenazine decanoate and benztropine regimens
Number of subjects: 46
Study 3057924 — intervention group
Group type: COMPARATOR
Intervention: Placebo as an adjunct to fluphenazine decanoate and benztropine regimens
Number of subjects: 46
Study 1124176 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (1000 patients)
Number of subjects: 4000
Study 1124176 — intervention group
Group type: COMPARATOR
Intervention: Control (2000 patients)
Number of subjects: 4000
Study 30808389 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone cessation app (Just Kwit!)
Number of subjects: 0
Study 30808389 — intervention group
Group type: COMPARATOR
Intervention: Usual care (patient-initiated follow up)
Number of subjects: 0
Study 28592288 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal recall of stool frequency
Number of subjects: 0
Study 28592288 — intervention group
Group type: COMPARATOR
Intervention: Direct observation using diapers (gold standard)
Number of subjects: 0
Study 25119509 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment with psychomotor therapy (PMT)
Number of subjects: 94
Study 25119509 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary treatment as usual without PMT
Number of subjects: 94
Study 25119509 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment with PMT
Number of subjects: 94
Study 22812594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2766
Study 22812594 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 2766
Study 22812594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2766
Study 21293087 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) 20 mg for 4 weeks, then OM 40 mg for 4 weeks (n = 420)
Number of subjects: 941
Study 21293087 — intervention group
Group type: COMPARATOR
Intervention: Losartan potassium (LOS) 50 mg for 4 weeks, then LOS 100 mg for 4 weeks (n = 469)
Number of subjects: 941
Study 21293087 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM)
Number of subjects: 941
Study 21293087 — intervention group
Group type: COMPARATOR
Intervention: Losartan potassium (LOS)
Number of subjects: 941
Study 18607729 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 430
Study 18607729 — intervention group
Group type: COMPARATOR
Intervention: Anxiety caseness
Number of subjects: 430
Study 17135808 — intervention group
Group type: EXPERIMENTAL
Intervention: In-clinic behavioral assessment
Number of subjects: 644
Study 17135808 — intervention group
Group type: COMPARATOR
Intervention: Telephonic administration of the same assessment
Number of subjects: 644
Study 17135808 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral measures of depression, anxiety, irritability, and apathy
Number of subjects: 644
Study 12923410 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8-16 mg once daily)
Number of subjects: 127
Study 12923410 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ, 25-50 mg once daily)
Number of subjects: 127
Study 11194516 — intervention group
Group type: EXPERIMENTAL
Intervention: p-HES (1000 ml)
Number of subjects: 20
Study 11194516 — intervention group
Group type: COMPARATOR
Intervention: c-HES (1000 ml)
Number of subjects: 20
Study 9527698 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical interventions
Number of subjects: 0
Study 9527698 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life scales
Number of subjects: 0
Study 9527698 — intervention group
Group type: EXPERIMENTAL
Intervention: N-of-1 trial
Number of subjects: 0
Study 8417271 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a hospital-based smoking-cessation intervention
Number of subjects: 1119
Study 8417271 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1119
Study 3565455 — intervention group
Group type: EXPERIMENTAL
Intervention: Native intravenous immunoglobulin (IVIG)
Number of subjects: 10
Study 3565455 — intervention group
Group type: COMPARATOR
Intervention: Modified intravenous immunoglobulin (IVIG)
Number of subjects: 10
Study 3565455 — intervention group
Group type: EXPERIMENTAL
Intervention: Native IVIG
Number of subjects: 10
Study 3565455 — intervention group
Group type: COMPARATOR
Intervention: Modified IVIG
Number of subjects: 10
Study 30471072 — intervention group
Group type: EXPERIMENTAL
Intervention: BPLN® (a mix of bioactive substances including a donor of nitric oxide, magnesium, and vitamins)
Number of subjects: 36
Study 30471072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 27696918 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR‐RE
Number of subjects: 60
Study 27696918 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed EMDR‐RE
Number of subjects: 60
Study 27696918 — intervention group
Group type: COMPARATOR
Intervention: CISD
Number of subjects: 60
Study 23683800 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg of daily zinc sulfate)
Number of subjects: 64
Study 23683800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same shape and color as zinc)
Number of subjects: 64
Study 22277061 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint action condition (2 models acting together)
Number of subjects: 48
Study 22277061 — intervention group
Group type: COMPARATOR
Intervention: Individual action condition (2 models acting individually)
Number of subjects: 48
Study 22277061 — intervention group
Group type: COMPARATOR
Intervention: Solitary action condition (1 model acting alone)
Number of subjects: 48
Study 20556817 — intervention group
Group type: EXPERIMENTAL
Intervention: ERB-041 (5 mg)
Number of subjects: 291
Study 20556817 — intervention group
Group type: EXPERIMENTAL
Intervention: ERB-041 (25 mg)
Number of subjects: 291
Study 20556817 — intervention group
Group type: EXPERIMENTAL
Intervention: ERB-041 (75 mg)
Number of subjects: 291
Study 20556817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 20556817 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 291
Study 18508226 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (TGC) 100 mg followed by 50 mg bid
Number of subjects: 846
Study 18508226 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (TGC)
Number of subjects: 846
Study 18508226 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (LEV) 500 mg bid
Number of subjects: 846
Study 18508226 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (LEV)
Number of subjects: 846
Study 17029520 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond XT (Group 1)
Number of subjects: 120
Study 17029520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-releasing adhesive (Kurasper F) (Group 2)
Number of subjects: 120
Study 17029520 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial self-etching primer (Clearfil Protect Bond) + Fluoride-releasing adhesive (Group 3)
Number of subjects: 120
Study 15281191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad mood induction in state-oriented participants
Number of subjects: 0
Study 15281191 — intervention group
Group type: COMPARATOR
Intervention: Participants able to downregulate negative affect (action-oriented participants)
Number of subjects: 0
Study 11083963 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide (250 mg per dose) plus nebulized salbutamol (0.2 mg/kg) and oral steroids (1 mg/kg)
Number of subjects: 102
Study 11083963 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nebulized salbutamol (0.2 mg/kg) and oral steroids (1 mg/kg)
Number of subjects: 102
Study 9387086 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 62
Study 9387086 — intervention group
Group type: COMPARATOR
Intervention: Viloxazine
Number of subjects: 62
Study 8466016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection at vastus lateralis
Number of subjects: 0
Study 8466016 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection at vastus lateralis
Number of subjects: 0
Study 8466016 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection at deltoid
Number of subjects: 0
Study 8466016 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection at deltoid
Number of subjects: 0
Study 3083913 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms twice daily
Number of subjects: 180
Study 3083913 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 180
Study 31557375 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion-inducing images
Number of subjects: 327
Study 31557375 — intervention group
Group type: COMPARATOR
Intervention: Neutral images (control)
Number of subjects: 327
Study 29578604 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health educator intervention
Number of subjects: 504